Structural and biochemical characterization of human orphan DHRS10 reveals a novel cytosolic enzyme with steroid dehydrogenase activity

Petra LUKACIK*1,2, Brigitte KELLER†, Gabor BUNKOCZI*, Kathryn KAVANAGH*, Wen HWA LEE*, Jerzy ADAMSKI† and Udo OPPERMANN**

*Structural Genomics Consortium, University of Oxford, Oxford OX3 7LD, U.K., and †GSF-National Research Center for Environment and Health, Institute for Experimental Genetics, Genome Analysis Center, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany

INTRODUCTION

HSDs (hydroxysteroid dehydrogenases) catalyse the oxidoreduction of hydroxy/oxo groups of steroid hormones and in this manner regulate intracellular availability of steroid ligands to their nuclear receptors, and constitute a pre-receptor control mechanism [1,2]. All mammalian HSDs characterized to date are members of the AKRs (aldo/keto reductases) [3], MDRs (medium-chain dehydrogenases/reductases), or the SDR (short-chain dehydrogenase/reductase) families, with the clear majority of HSDs belonging to the latter family [4,5]. The main steroid-metabolizing activities regulating ligand access are oxidoreductases acting on positions 3, 11, 17 and 20, depending on the steroid hormone class. Whereas 3(α/β)-HSDs are involved in metabolism of all classes of steroid hormones, and 11α-HSDs and 20(α/β)-HSDs are restricted to glucocorticoids and progestins, 17β-HSDs play a central role in androgen and oestrogen physiology. At present, 13 different isoforms of 17β-HSDs have been characterized, and with the exception of 17β-HSD5 all are members of the SDR family [6–8]. They differ in nucleotide cofactor [NAD(H) or NADP(H)] and steroid substrate (androgen/oestrogen) specificity, subcellular compartmentalization and tissue-specific expression patterns. Accordingly, 17β-HSDs are numbered in chronological order according to their date of discovery. These HSDs can be grouped into in viva oxidative enzymes (17β-HSD type 2, 4, 6, 8, 9, 10, 11 and 12) catalysing the NAD+-dependent inactivation of steroid receptor ligands, or into in vitro reductive enzymes (17β-HSD type 1, 3, 5 and 7) which are NADPH-dependent and whose localization of DHRS10. Along with tissue expression data, this suggests a role for DHRS10 in the local inactivation of steroids in the central nervous system and placenta. The crystal structure of the DHRS10 apoenzyme exhibits secondary structure of the SDR (short-chain dehydrogenase/reductase) family: a Rossmann-fold with variable loops surrounding the active site. It also reveals a broad and deep active site cleft into which NADH and oestradiol can be docked in a catalytically competent orientation.

Key words: crystal structure, DHRS10, 17β-hydroxysteroid dehydrogenase, pre-receptor control, short-chain dehydrogenase/reductase, steroid metabolism.

EXPERIMENTAL

Cloning of human DHRS10

A cDNA coding for human DHRS10 was obtained by gene synthesis using codon optimization for expression in Escherichia coli (Genscript). The insert DNA was subcloned into a bacterial pET-based expression vector, in frame into NdeI and BamHI sites of the pET21a (Novagen).

Abbreviations used: DHEA, dehydroepiandrosterone; ER, oestrogen receptor; GFP, green fluorescent protein; HEK-293T cells, HEK-293 cells (human embryonic kidney cells) expressing the large T-antigen of SV40 (simian virus 40); HSD, hydroxysteroid dehydrogenase; MDR, medium-chain dehydrogenase/reductase; NCS, non-crystallographic symmetry; RMSD, root mean square deviation; SDR, short-chain dehydrogenase/reductase; TCEP, tris-(2-carboxyethyl)phosphine.

1 Present address: Laboratory of Molecular Biology, NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), National Institutes of Health, 50 South Drive, Room 4507, Bethesda, MD 20892-8030, U.S.A.

2 Correspondence may be addressed to either of these authors (email lukacikp@niddk.nih.gov or udo.oppermann@sgc.ox.ac.uk).

The structural co-ordinates of DHRS10 apoenzyme reported were deposited in the Protein Data Bank under the code 1YDE.
sites, resulting in a variant containing an N-terminal His\textsubscript{6} tag, followed by a TEV (tobacco etch virus) protease cleavage site. For expression in cell culture or for Northern-blot analysis, human DHRS10 cDNA was amplified from HEK-293T [HEK-293 cells (human embryonic kidney cells) expressing the large T-antigen of SV40 (simian virus 40)] cDNA using PCR with specific primers [for Northern blot, probe forward: 5′-GAGGTGAAAGAGGC-CCAGAGTAG-3′, reverse: 5′-GTGACCCGGCACCTTGCTA-AC-3′; for cloning into pcDNA3 (Invitrogen): 5′-TATAGGATCTCAGAAGGATACCCGGTGC-3′, reverse: 5′-TAAACGGATCCGAGATACCGAAGGATACCCGGTGC-3′; for cloning into pcDNA4 Myc-His (Invitrogen): 5′-TATAGGATCTCAGAAGGATACCCGGTGC-3′, reverse: 5′-TAAACGGATCCGAGATACCGAAGGATACCCGGTGC-3′; for cloning into pEGFP-C2 (BD Biosciences, Heidelberg, Germany): 5′-TATAGGATCTCAGAAGGATACCGAAGGATACCCGGTGC-3′, reverse: 5′-TAAACGGATCCGAGATACCGAAGGATACCCGGTGC-3′]. Inserts were verified by dideoxy sequence analysis using vector-specific primers. For transfection, DNA was isolated using the PureYield Midi kit (Promega, Mannheim, Germany) according to the manufacturer’s instructions.

**Heterologous expression in *E. coli* and purification of recombinant protein**

The plasmid was transformed into Rosetta 2 (DE3) strain, and cells were grown overnight in 1 litre of Terrific Broth containing 34 µg/ml chloramphenicol and 100 µg/ml ampicillin in a 2.5 litre
baffled flask at 37°C. Protein expression was induced by addition of 100 µM IPTG (isopropyl β-D-thiogalactoside) to cells that had been grown to a D_{600} of 0.6. The temperature was lowered to 15°C and the culture was continued for a further 20 h. The cells were harvested and stored at −80°C. The frozen cell pellet was resuspended in 30 ml of 50 mM Hepes (pH 7.5), 500 mM NaCl, 5 mM imidazole and 0.5 mM TCEP [tris-(2-carboxyethyl)phosphine]. The cells were then disrupted using a high-pressure homogenizer (Emulsiflex-C5, Avestin). Following centrifugation (35000 g, 40 min and 4°C) the clarified supernatant was passed through a 10 ml DE-52 column to remove DNA. The flow through was applied to a 2 ml Ni-NTA (Ni^{2+}-nitrilotriacetic acid; Qiagen) column, washed with 20 ml of 50 mM Tris/HCl (pH 7.5), 500 mM NaCl, 5 mM imidazole and 0.5 mM TCEP and eluted by raising the imidazole concentration to 250 mM. The eluted peak was loaded on to an S75 16/60 prep grade (GE/Amersham) gel filtration column (35 000×1 500 000 Å²) in 20 mM NaCl, 5 mM imidazole and 0.5 mM TCEP [tris-(2-carboxyethyl)phosphine] buffer. After flash freezing in liquid nitrogen, the protein was stored at −15°C for further analysis by crystallization or substrate screening.

Crystallography and structure determination

Crystals were grown by the sitting drop vapour diffusion method in 24-well sitting drop CrysChem plates (Hampton Research) at 20°C. The concentrated protein (2 µl) was mixed with 2 µl of 0.2 M magnesium acetate, 0.1 M sodium cacodylate (pH 6.5) and 20% (v/v) glycerol and 0.5 mM TCEP. The essentially pure DHRS10-containing peak was concentrated (Vivaspin 20; Vivascience; molecular-mass cut-off 15 kDa) to a final concentration of 12 mg/ml. After flash freezing in liquid nitrogen, the protein was stored at −80°C for further analysis by crystallization or substrate screening. The mass of the purified product was verified by LC (liquid chromatography)/MS on an Agilent LC/MSD TOF (time-of-flight) system (Agilent).

Ligand docking

Two consecutive ligand docking procedures were performed according to the methodology described by Abagyan and Totrov [16,17] and implemented in the program ICM version 3.4.1: one to position the NAD⁺ molecule into the cofactor-binding pocket and a second one to dock the oestradiol molecule into the active site of DHRS10. In both cases, grid maps representing different properties of the enzyme were computed. During the docking, either one of the torsional angles of the ligand was randomly changed or a pseudo-Brownian move was performed. Each random change was followed by 100 steps of local conjugate-gradient minimization. The new conformation was accepted or rejected according to metropolis criteria using a temperature of 600 K. The length (number of Monte Carlo steps) of the docking run as well as the length of local minimization was determined automatically by an adaptive algorithm, depending on the size and number of flexible torsions in the ligand. The lowest energy conformation satisfying the absence of clashes after docking NAD⁺ was incorporated into the structure file of DHRS10 and this was in turn used as receptor for the docking of oestradiol. In this second docking, a positional restraint was imposed on the O17 atom of oestradiol and the Tyr154-OH, based on the catalytic mechanism of SDR enzymes [18,19].

Substrate screening and kinetic analysis of purified recombinant human DHRS10

A compound library comprising 50 different steroids (androgen, oestrogen, progester, glucocorticoid hormones, bile acids and oxysterols; obtained from Sigma and Steraloids) with hydroxy/keto functions at position 3, 7, 11, 17, 20 and 21 were screened against purified human DHRS10 using a fluorescence-based assay on cofactor fluorescence change in a SpectraMax M2 microplate reader (Molecular Devices). Steroids were dissolved in DMSO with stock solutions ranging from 5 to 20 mM, and were further diluted 1:1000 in the assay mixture (oxidation: 50 mM Tris/HCl, pH 8.5, 100 mM NaCl, 200 µM NAD⁺ or NADP⁺ and 50–100 µg/ml enzyme; reduction: 50 mM Tris/HCl, pH 7.5, 100 mM NaCl and 10 µM NADH or NADPH). Excitation was set to 340 nm, emission was at 460 nm, and the assay was conducted in 96-well plates (Costar). Initial hits from this screen were verified by analysis of product formation using radioactively labelled steroids with an HPLC system coupled with online radioactivity detection. Kinetic analysis was carried out in 96-well plates as described above, or in single, 10 mm pathlength quartz cuvettes, by varying steroid substrate (200 nM–100 µM) and cofactor (0.1 µM–10 mM) concentrations. Initial velocities were converted into product formation using freshly prepared nucleotide cofactor solutions as standards, and data obtained were fitted by non-linear regression to the Michaelis–Menten equation using SigmaPlot or GraphPad software packages.

Cell culture and transfection

HEK-293T, SaOS-2 and HeLa cells were grown under humidified standard conditions (37°C and 5% CO₂) in high-glucose Dulbecco’s modified Eagle’s medium (Invitrogen, Karlsruhe, Germany) supplemented with 10% (v/v) foetal bovine serum (Biochrom AG, Berlin, Germany), 2 mM L-glutamine (Invitrogen) and 100 units/ml penicillin/100 µg/ml streptomycin. For transfection, FuGENETM 6 transfection reagent (Roche Biosciences, Mannheim, Germany) was used according to the manufacturer’s instructions. For metabolite analysis, HEK-293T cells were seeded on to 12-well plates (Nunc, Wiesbaden, Germany) and grown overnight before transfection. Twenty-four hours after transfection, 1 µl of [2,4,6,7-3H(N)]oestradiol (final concentration 20 nM) (PerkinElmer, Wellesley, MA, U.S.A.) was added to cell culture medium and incubation was continued. Cell culture medium was collected at different time points, and purified with StrataC18E columns (Phenomenex, Aschaffenburg, Germany). Samples were then analysed on HPLC (Beckman, Fullerton, CA, U.S.A.) with 43% (v/v) acetonitrile (in water) on a Luna C18 column (Phenomenex). Conversion rates were obtained after integration of chromatograms and evaluated with 24Karat-software (Beckman). For analysis of subcellular localization, HeLa or SaOS-2 cells were seeded on to coverslips. After 24 h, cells were
transfected and grown for a further 24 h. For counterstaining of mitochondria MitoTracker Orange was used, for nuclear counterstaining Hoechst 33342 and for F-actin counterstaining, Alexa Fluor® 568 phalloidin (all Invitrogen). For immunochemical detection of the Myc tag 9B11 mouse monoclonal antibody (Cell Signaling Technology, NEB, Frankfurt a.M., Germany) was used as the primary antibody and the secondary antibody was Alexa Fluor® 488 goat anti-mouse IgG (Invitrogen). After fixation and staining, coverslips were mounted on to slides using Vectashield (Vector Laboratories, Burlingame, CA, U.S.A.). Subcellular localization was analysed by Zeiss Axiophot fluorescence microscope (Carl Zeiss, Oberkochen, Germany) with the ISIS (MetaSystems, Altlußheim, Germany) image processing software.

Expression analysis of DHRS10 in human tissues

FirstChoice Northern Blot Human Blot II (Ambion) was used with recommended wash solutions and Ultrahyb hybridization solution according to the manufacturer’s instructions. The PCR product used as a probe for Northern blot was labelled with a Strip-EZ DNA kit (Ambion, Huntington, U.K.). Radioactively labelled nucleotides were purchased from Amersham Biosciences (Uppsala, Sweden). Detection was by autoradiography using BioMax XAR films (Kodak Industrie, Chalon-sur-Saône, Cedex, France).

RESULTS

Expression, purification and activity of human DHRS10

Full-length DHRS10 was expressed and purified in a two-step chromatographic procedure yielding approx. 20 mg/l of culture. The purified protein was judged homogeneous by SDS/PAGE and MS (results not shown), and was found suitable for subsequent use in substrate screening, kinetic and crystallographic studies. A fluorescent assay was used to carry out substrate screening against a collection of different steroids. Purified DHRS10 enzyme converted NAD\(^+\) into NADH in the presence of oestradiol, testosterone or 5-androstene-3β,17β-diol. Michaelis–Menten kinetics were observed for oestradiol and 5-androstene-3β,17β-diol; with \(K_v\) values of 5.6 ± 1.7 and 13.6 ± 1.6 \(\mu\)M and \(V_{max}\) values of 2.5 ± 1.0 and 9.1 ± 1.6 nmol of NADH · min\(^{-1}\) · mg\(^{-1}\) for oestradiol and 5-androstene-3β,17β-diol respectively. However, non-saturable kinetics were found for testosterone (Figure 2, Table 1). No conversion was observed in the presence of NADP(H) or with \(\beta\)-OH-butyryl CoA, which is a bona fide substrate for other 17\(\beta\)-HSDs such as 17\(\beta\),17\(\alpha\)-HSD4 and 17\(\beta\)-HSD10 (Table 1).

DHRS10 activity in intact cells

In order to verify steroid conversion by DHRS10 in intact cells and to investigate the direction of the DHRS10 reaction \textit{in vivo}, HEK-293T cells were transfected with an expression plasmid encoding DHRS10 and exposed to 20 nM radiolabelled oestradiol. The transfected cells efficiently oxidized oestradiol to oestrone as revealed by HPLC analysis of the supernatant (Figure 2B). This conversion rate is significantly higher compared with that of mock-transfected cells (pcDNA3 vector only). Therefore intact cells expressing DHRS10 can indeed oxidize steroids at physiological concentrations.

Crystal structure of DHRS10

Following extensive crystallization trials, the purified protein yielded well diffracting crystals suitable for crystallographic analysis.
Characterization of human DHRS10

Table 2  Data processing and refinement statistics for DHRS10 crystal structure

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Data processing</strong></td>
<td></td>
</tr>
<tr>
<td>Wavelength (Å)</td>
<td>0.9794</td>
</tr>
<tr>
<td>Space group</td>
<td>P1211</td>
</tr>
<tr>
<td>Unit cell parameters (Å, °)</td>
<td>167.1, 98.8, 167.5, 90.0, 115.9, 90.0</td>
</tr>
<tr>
<td>Resolution range (outer shell) (Å)</td>
<td>82.6–2.4 (2.5–2.4)</td>
</tr>
<tr>
<td>Observed reflections (outer shell)</td>
<td>558,993 (13,185)</td>
</tr>
<tr>
<td>Unique reflections (outer shell)</td>
<td>176,307 (12,096)</td>
</tr>
<tr>
<td>Completeness (outer shell) (%)</td>
<td>91.9 (55.2)</td>
</tr>
<tr>
<td>Mean I/σI (outer shell)</td>
<td>9.1 (1.6)</td>
</tr>
<tr>
<td>Multiplicity (outer shell)</td>
<td>2.9 (1.1)</td>
</tr>
<tr>
<td>Rmerge (outer shell)</td>
<td>0.117 (0.575)</td>
</tr>
<tr>
<td>V_M (Å^3·Da^-1)</td>
<td>2.5</td>
</tr>
<tr>
<td><strong>Refinement</strong></td>
<td></td>
</tr>
<tr>
<td>Protein atoms</td>
<td>29,419</td>
</tr>
<tr>
<td>Protein residues (per chain)</td>
<td>A, 250; B, 247; C, 250; D, 255; E, 250; F, 256; G, 247; H, 254; I, 247; J, 255; K, 250; L, 255; M, 244; N, 240; O, 247; P, 254</td>
</tr>
<tr>
<td>Water molecules in model</td>
<td>1251</td>
</tr>
<tr>
<td>R_wilx</td>
<td>0.181</td>
</tr>
<tr>
<td>R_free</td>
<td>0.229</td>
</tr>
<tr>
<td>RMSD</td>
<td>0.016</td>
</tr>
<tr>
<td>Bond angles (°)</td>
<td>1.505</td>
</tr>
<tr>
<td>Average B factor (Å^2)</td>
<td></td>
</tr>
<tr>
<td>Main chain (per chain)</td>
<td>4.485</td>
</tr>
<tr>
<td>Side chain (per chain)</td>
<td>7.187</td>
</tr>
<tr>
<td>Water molecules</td>
<td>4.650</td>
</tr>
<tr>
<td>PDB code</td>
<td>1YDE</td>
</tr>
</tbody>
</table>

The crystal structure of DHRS10 was solved by molecular replacement to a resolution of 2.4 Å, and a summary of the data processing and refinement statistics is compiled in Table 2. The asymmetric unit contains 16 DHRS10 monomers arranged as four tetramers with 222-point group symmetry. Each monomer comprises two distinct regions (Figure 3): the first region is a Rossmann-fold built up of a central β-sheet core consisting of seven parallel β-strands (βA–βG) sandwiched between two arrays of parallel helices (αB–αG). This region has a characteristic nucleotide cofactor [NAD(H) or NADP(H)]-binding motif T-G-X_3-G-X-G located near its N-terminus. Residue Asp40 is present at the C-terminal end of the second β-strand (βB). In SDR structures the presence of an acidic residue at this location indicates a NAD(H) versus NAD(P) selectivity, since the carboxylate group is in a favourable location to interact with the 2’- and 3’-OH groups of the adenosine ribose of NAD. Accordingly, this residue prohibits NADP(H) binding by repelling the negative charge on the 2’-phosphate and thus confers NAD(H) specificity to DHRS10 [20]. Kinetic analysis (see above) confirmed NAD(H) as the cofactor for the DHRS10 reaction. Also within this region is a very short α-helix (αEF) inserted between αE and βF and encompassing residues 142–147. A second region contains two additional α-helical elements αFG1 (residues 189–197) and αFG2 (residues 201–212) that are inserted between βF and αG. As with all SDRs whose structures have been determined so far, this second region is more variable and is responsible for substrate binding.

In the apostructure determined, a broad active site cleft lies between the two regions (Figures 3 and 5). Apart from the highly conserved catalytic triad that consists of Ser141, Tyr154 and Lys158, this active site cleft contains a number of hydrophobic residues potentially involved in binding of hydrophobic substrates (Figure 4).

The side chain of the catalytic Tyr154 is shown in stick representation. (All structural representations were drawn with the program PyMOL.)

Figure 3  The secondary structure of DHRS10

Figure 4  Detailed view of the active site of DHRS10

Modelled NAD^+ and oestradiol (E2) are shown in grey stick representation and side chains of residues belonging to DHRS10 are shown in dark grey stick representation. The distance measurement (3.4 Å) between C-4 of nicotinamide and C-17 of the steroid is shown in black dashed line and other polar contacts under 3.2 Å are shown in unlabelled dashed lines.

Ligand docking into the DHRS10 active site

Although numerous co-crystallization experiments were attempted, DHRS10 crystallized as an apoenzyme with no cofactor or substrate in the active site. In order to understand the interactions of DHRS10 with its cofactor and substrate on a molecular level, in silico ligand docking was performed on the protein monomer. Starting models for the oestradiol substrate and NAD^+ cofactor were obtained from the crystal structure of rat 17β-HSD10 (also...
The panels on the left show the various structures in ribbon representation set at 80% transparency and the panels on the right show the structures in the same orientation in surface representation. (a) The structure of DHRS10 apoenzyme (PDB code 1YDE) with modelled NAD$^+$ and oestradiol (E2) shown in grey stick representation. The catalytic residues Tyr$^{154}$, Lys$^{158}$ and Ser$^{141}$ are in orange stick representation. (b) The crystal structure of the 17$\beta$-HSD1 ternary complex containing NADP$^+$ (NAP) and oestradiol (E2) (PDB code 1FD1). The catalytic residues Tyr$^{155}$, Lys$^{159}$ and Ser$^{142}$ are shown in cyan stick representation. (c) The structure of the 17$\beta$-HSD1 (PDB code 1BHS) apoenzyme. The catalytic residues are shown in blue stick representation.

Figure 5 Comparison of the DHRS10 structure with the structures of ternary complex and apoenzyme 17$\beta$-HSD1

The panels on the left show the various structures in ribbon representation set at 80% transparency and the panels on the right show the structures in the same orientation in surface representation. (a) The structure of DHRS10 apoenzyme (PDB code 1YDE) with modelled NAD$^+$ and oestradiol (E2) shown in grey stick representation. The catalytic residues Tyr$^{154}$, Lys$^{158}$ and Ser$^{141}$ are in orange stick representation. (b) The crystal structure of the 17$\beta$-HSD1 ternary complex containing NADP$^+$ (NAP) and oestradiol (E2) (PDB code 1FD1). The catalytic residues Tyr$^{155}$, Lys$^{159}$ and Ser$^{142}$ are shown in cyan stick representation. (c) The structure of the 17$\beta$-HSD1 (PDB code 1BHS) apoenzyme. The catalytic residues are shown in blue stick representation.

known as type II 3-hydroxyacyl-CoA dehydrogenase, PDB code 1E6W). The in silico docking of NAD$^+$ yielded a very satisfactory conformation for both protein and cofactor. The docked NAD$^+$ molecule presented an RMSD (root mean square deviation) of 0.855 Å for all atoms when compared with the NAD$^+$ cofactor of type II 3-hydroxyacyl-CoA dehydrogenase. The small difference was expected since the cofactor-binding pocket is not completely conserved and small variations in the binding pose are expected in these situations. In spite of this, the overall geometry of the DHRS10-binding pocket has been preserved and NAD$^+$ could be docked in a manner very similar to that observed in 1E6W.

The docking of oestradiol to the DHRS10–NAD$^+$ model can be achieved by placing the atom O-17 of oestradiol within the proximity of the catalytic tyrosine (Tyr$^{154}$) while keeping the atom C-17 close enough to C-4 of the nicotinamide for hydride transfer during catalysis (3.4 Å) (Figure 4). Consequently the C-17 hydroxyl is within hydrogen-bonding distance of Tyr$^{154}$ (3.2 Å) and Ser$^{141}$ (3.0 Å). In this conformation the remainder of the environment of the oestradiol molecule is made up of a mixture of polar and non-polar residues: His$^{93}$, Val$^{147}$, Gln$^{148}$, Trp$^{192}$ and Asn$^{186}$ lie within 4 Å of the oestradiol molecule and contribute to van der Waals interactions with oestradiol. There are no residues that contribute to additional hydrogen bonding with oestradiol.

A structural comparison of DHRS10 with docked NAD/oestradiol was carried out with the crystal structure of the ternary complex of 17$\beta$-HSD1 with NADP/oestradiol (PDB code 1FD1), apo-17$\beta$-HSD1 (PDB code 1BHS) and to other structures of members of the 17$\beta$-HSD family. The DHRS10 molecule possesses a prominent broad and open active site cleft that is not observed in 17$\beta$-HSD1 (Figure 5) or other 17$\beta$-HSDs (results not shown). Within this cleft the docked oestradiol molecule sits rather loosely. Again this is in contrast with 17$\beta$-HSD1 where oestradiol
interactions are better defined. Here, the oestradiol is stabilized by three rather than two hydrogen bonds: two to the catalytic serine and tyrosine residues and an additional hydrogen bond between oestradiol O3 and Ne2 of His221 [21]. Additionally, a number of neighbouring residues contribute to hydrophobic interactions with the core of the steroid.

Nonetheless the docking procedure employed within does not take into account the possible conformational changes to the DHRS10 structure induced by binding of cofactor or substrate. Consequently, the milieu of the oestradiol could be significantly different in the secondary or tertiary complex of DHRS10.

Interestingly, a comparison of the apo and ternary complex structure of 17β-HSD1 reveals that although some structural rearrangement does occur in the loop connecting βF and eFG1, overall the active site remains closed in both structures (Figure 5).

**Subcellular localization of DHRS10**

Immunofluorescence subcellular localization studies were carried out where a DHRS10 construct with a Myc tag at its N-terminus was probed with a primary anti-Myc monoclonal mouse antibody and a secondary fluorescent antibody. To eliminate the possibility of the N-terminal tag interfering with the proper targeting of the DHRS10 protein, *in situ* fluorescence experiments were also carried out on HeLa cells expressing human DHRS10 with a GFP (green fluorescent protein) tag at its C-terminus. In both cases the studies clearly reveal the cytoplasmic localization of DHRS10 protein (Figure 6). No mitochondrial or nuclear targeting could be observed using fluorescent mitochondrial (results not shown) and nuclear reporter dyes.

**Expression analysis of DHRS10 in human tissues**

Northern-blot analysis using a radioactively labelled probe of DHRS10 was carried out on selected human tissues (Figure 7). High expression is observed in brain, liver and placenta, whereas no or low signals are observed in small intestine, colon, pancreas, spleen and gonads (testes and ovary). Two distinct sizes of specific signals are observed (∼5.5 and 7 kbp), indicating two distinct transcription or splicing sites in brain and placenta, whereas in liver only one mRNA species is observed (Figure 7).

**DISCUSSION**

In the present study, we have identified DHRS10 as a cytosolic SDR enzyme with 17β-HSD activity on steroid substrates. Out of the human tissues investigated the highest levels of DHRS10 expression were observed in the brain, liver and placenta.

The DHRS10 gene was initially cloned in an attempt to define retinoid metabolizing enzymes; however, this function was excluded after heterologous expression [9]. To our knowledge, no further functional studies are available on this human gene or any mammalian orthologue. To investigate the structural and functional features of the enzyme, we determined the crystal structure and correlated these results to functional analyses. To this end, experimental structure determination appears to be essential to derive functional conclusions. We performed homology modelling of human DHRS10 using the two closest available structures as templates, namely Rv2002 gene product from *Mycobacterium tuberculosis* (PDB code 1NFQ) and TT0321 from *Thermus thermophilus* HB8 (PDB code 2D1Y), both with 38% sequence identity. Although the predicted folding was very similar to the experimental structure, and homology modelling could be performed in a satisfactory manner for most of the molecule, an important active site segment comprising ∼14 residues was not correctly predicted due to high sequence variation. Thus a docking analysis to suggest possible substrates for de-orphanization of DHRS10 could not be carried out due to the lack of reliable templates for this critical portion of the structure. Structure prediction for a segment with such size to the level required for de-orphanization via docking methods is therefore still beyond the reach of present technology.

In common with most of the 17β-HSDs, the crystal structure displays the typical characteristics of the SDR family with a largely conserved fold and the presence of catalytically important residues, Asn114, Ser141, Tyr154 and Lys158 (Figure 1) [19]. Interestingly, a deep and broad active site cleft is found within the DHRS10 structure. This feature is more prominent than in other...
17β-HSDs for which three-dimensional structures have been determined to date. As well as demonstrating that this protein converts 17β-OH steroids such as oestradiol into oestrone both in vivo and in vitro, we also show that NAD" and oestradiol can be docked within the cleft in a catalytically competent conformation. The present study reveals the molecular details of the enzyme–substrate–cofactor interaction and shows that the oestradiol substrate sits rather loosely within the active site cleft. Such a conformation has several possible implications. First, it might explain the low catalytic turnover value for the in vitro DHRS10 reaction. However, the low kcat value for DHRS10 is not entirely unusual and a number of other SDR enzymes have similarly low kcat values for substrates that have nevertheless been shown to be relevant in their physiological context. The latter is exemplified by human 11β-HSD1, which carries out metabolic activation of the glucocorticoid hormone cortisol from the precursor cortisone. The determined kcat for cortisone reduction is only approx. 20 times higher [22] than the kcat value for the DHRS10/NAD"/oestradiol reaction, yet the in vivo importance of this reaction has been demonstrated on a number of occasions and is highlighted by its involvement in metabolic diseases such as obesity and insulin resistance [23–26]. Furthermore, human 17β-HSD10 displays an approx. 10-fold higher kcat than DHRS10/NAD"/oestradiol [22]; however, the Kc of 17β-HSD10 for this reaction is approx. 5-fold higher, suggesting that 17β-HSD10 and DHRS10 have similar kcat/Kc values. Secondly, the broad active site cleft suggests that the DHRS10 enzyme might have other substrate specificities besides oestradiol since the active site cleft is wide enough to accommodate larger substrates than steroid molecules. This broad substrate spectrum appears to be a hallmark for 17β-HSDs, and accordingly, broad substrate specificity has been demonstrated for a number of 17β-HSDs such as type 4, 6 and 10 [2,8]. In addition, wider substrate specificity of DHRS10 is also possible, as deduced from a phylogenetic analysis that shows that DHRS10 clusters with SDR proteins such as PECR (peroxisomal trans-2-enoyl-CoA reductase) [27,28] and mitochondrial DECR1 (2,4-dienoyl CoA reductase 1) [29,30] whose primary roles are in converting fatty-acyl CoAs rather than steroids (results not shown). However, an initial screen with a limited number of compounds (comprising >200 compounds including CoA derivatives) as possible substrates or ligands for SDR enzymes did not reveal any significant binding except for oestrogen-based steroids (results not shown). Thirdly, it is also possible that the extensive and open active site cleft is a feature of the apoenzyme and that the cleft might undergo a conformational change and close when ligands are bound.

Together with the expression observed in tissues such as liver, brain and placenta, the proven in vivo and in vitro functions of DHRS10 as oxidative 17β-hydroxy dehydrogenase suggest possible roles for DHRS10 in the local regulation of active steroid hormones levels [1,2]. DHRS10 would therefore be responsible for steroid inactivation similar to 17β-HSD2. However, as shown in the present study, the tissue distribution of DHRS10 is distinct from that reported for type 2 [31,32] and because of that a tissue-specific function is postulated. This is in analogy to other 17β- or 11β-HSD enzymes that constitute critical determinants of steroid hormone physiology [1]. It appears in several situations essential that steroid ligands are excluded from their receptors, as is the case with glucocorticoids and the mineralocorticoid receptor.

Our in vitro results indicate that DHRS10 is involved in the local inactivation of 5-androstene-3β,17β-diol and of oestradiol, and taken together with the initial expression data obtained in the present study, suggest possible functional roles mainly in the placenta and the central nervous system. The activity and expression in the central nervous system thus adds DHRS10 isoenzyme to the complexity of oestrogen and DHEA (dehydroepiandrosterone)-metabolizing steroid dehydrogenases observed in a study conducted by Steckelbroeck et al. [33], noting multiple 17β-HSDs involved in human brain tissues. The weak oestrogenic steroid 5-androstene-3β,17β-diol is an important metabolic intermediate in the peripheral sex steroid synthesis starting from DHEA. 5-Androstene-3β,17β-diol is secreted by the adrenal gland, and like the sex steroids display important functions in the brain such as hippocampal neurogenesis and neural survival [34]. Oestrogens have an extensive range of effects on the brain [35]. These include effects on brain development [36], centrally regulated effects on reproduction, mood [37], cognition [38], protection from neurotoxins/neurodegeneration or injury [39,40], neuron plasticity [41], transcription of neuropeptides [42] and regulative effects on the enzymes that affect the synthesis and turnover of classical neurotransmitters, e.g. serotonin [43] and dopamine [44].

It is clear that the cytosolic localization of DHRS10 could allow ‘control by access’ by limiting exogenously and endogenously produced active oestrogen (oestradiol) from reaching ERs (oestrogen receptors) ERs/β located in the nucleus. Interestingly, surface membrane-associated ERs, whose existence has also been recently demonstrated [45,46], would allow bypass of such a control.

Taken together, we have provided a structural and functional characterization of an as yet poorly documented mammalian gene product. Further studies concerning temporal and spatial expression patterns, animal studies, as well as a search for other possible substrate activities will be mandatory for the additional characterization of this SDR member.

The Structural Genomics Consortium is a registered charity (number 1097737) funded by the Wellcome Trust, GlaxoSmithKline, Genome Canada, the Canadian Institutes of Health Research, the Ontario Innovation Trust, the Ontario Research and Development Challenge Fund, the Canadian Foundation for Innovation; Vinnova, Knut and Alice Wallenberg Foundation; and Karolinska Institutet. Data collection by Dr F. von Delft (Structural Genomics Consortium, University of Oxford, Oxford, U.K.) is gratefully acknowledged.

REFERENCES